Laboratory of Parasitology, Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke 9820, Belgium.
Laboratory of Parasitology, Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke 9820, Belgium.
Vet Parasitol. 2024 Jun;328:110179. doi: 10.1016/j.vetpar.2024.110179. Epub 2024 Mar 31.
In this study the efficacy of an intramuscular formulation of toltrazuril combined with gleptoferron for the control of porcine cystoisosporosis caused by Cystoisospora suis was investigated. The study was carried out on three Belgian farms with a confirmed history of C. suis infections. As none of the farms implemented a standardized toltrazuril treatment regimen for their piglets, the presence of resistant C. suis strains seems improbable. In total 90 litters, representing 1249 piglets, were included in the study and randomly allocated to either the treatment or control group. Piglets in the treatment group received a single intramuscular injection, containing 45 mg toltrazuril and 200 mg gleptoferron, between 1 and 3 days of age. Piglets in the control group received a single injection with only 200 mg gleptoferron. The effect of treatment on oocyst excretion, expressed in oocysts per gram of feces (OPG), average daily weight gain (ADG) and mortality was determined both pre- and post-weaning. A significant decrease in OPG as well as a decrease in the number of litters (pre-weaning) and pens (post-weaning) that tested positive for cystoisosporosis, was observed in the treated animals compared to the controls. Furthermore, treatment resulted in an increased ADG during the period from day 1 to day 21 (p-value: 0.03881). There was no significant difference in mortality observed between the treatment group to the control group (p-value: 0.2167). To our knowledge, this is the first report on the effect of toltrazuril on oocyst excretion after weaning. This finding highlights the potential long-term benefits of the treatment beyond the initial administration.
在这项研究中,研究了妥曲珠利与格莱氟苯联合肌肉注射治疗由猪等孢球虫引起的猪囊虫病的疗效。该研究在三个有明确猪等孢球虫感染史的比利时农场进行。由于这些农场都没有为仔猪制定标准化的托曲珠利治疗方案,因此不太可能存在耐药性猪等孢球虫菌株。共有 90 窝,代表 1249 头仔猪,被纳入研究,并随机分配到治疗组或对照组。治疗组的仔猪在 1 至 3 日龄时接受一次肌肉注射,剂量为 45mg 妥曲珠利和 200mg 格莱氟苯。对照组的仔猪接受仅含 200mg 格莱氟苯的单次注射。在断奶前和断奶后,分别测定了治疗对卵囊排泄(以粪便中的卵囊数(OPG)表示)、平均日增重(ADG)和死亡率的影响。与对照组相比,治疗组的 OPG 显著降低,囊虫病阳性的窝数(断奶前)和栏数(断奶后)减少。此外,治疗组在第 1 天至第 21 天期间的 ADG 增加(p 值:0.03881)。治疗组与对照组之间的死亡率无显著差异(p 值:0.2167)。据我们所知,这是关于妥曲珠利在断奶后对卵囊排泄影响的首次报道。这一发现突出了治疗的潜在长期益处,超出了最初的给药。